Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  The Lancet

• Publication date

  2014-10-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(14)60976-4PMID 25018121
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• GLP-1 receptor agonists: why is once weekly inferior to once daily?

  2014cited by this paper
• Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)

  2014cited by this paper
• Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal‐F1)

  2014cited by this paper
• Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities.

  2014cited by this paper
• Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.

  2014cited by this paper
• Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)

  2014cited by this paper
• Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)

  2014cited by this paper
• Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.

  2013cited by this paper
• Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2013cited by this paper
• Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379

  2013cited by this paper
• Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2013cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

  2012cited by this paper
• Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets

  2012cited by this paper
• GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

  2012cited by this paper
• Test–Retest, Responsiveness, and Minimal Important Change of the Ability to Perform Physical Activities of Daily Living Questionnaire in Individuals with Type 2 Diabetes and Obesity

  2012cited by this paper
• Tu1502 Longitudinal Monitoring of Lipase and Amylase in Adults With Type 2 Diabetes and Obesity: Evidence From Two Phase 3 Randomized Clinical Trials With the Once-Daily GLP-1 Analog Liraglutide

  2012cited by this paper
• Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2012cited by this paper
• A 5‐week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long‐acting glucagon‐like peptide‐1 analogue, in patients with type 2 diabetes

  2011cited by this paper
• Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

  2011cited by this paper
• LY2189265, a long‐acting glucagon‐like peptide‐1 analogue, showed a dose‐dependent effect on insulin secretion in healthy subjects

  2011cited by this paper
• Ability to Perform Daily Physical Activities in Individuals with Type 2 Diabetes and Moderate Obesity: A Preliminary Validation of the Impact of Weight on Activities of Daily Living Questionnaire

  2011cited by this paper
• DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

  2011cited by this paper
• Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.

  2010cited by this paper
• Engineering and characterization of the long‐acting glucagon‐like peptide‐1 analogue LY2189265, an Fc fusion protein

  2010cited by this paper
• Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD) (Diabetes Care (2009) 32, (1224-1230))

  2010cited by this paper
• Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

  2009cited by this paper
• Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

  2009cited by this paper
• Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

  2009cited by this paper
• Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.

  2008cited by this paper
• Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes

  2008cited by this paper
• General Multistage Gatekeeping Procedures

  2008cited by this paper
• Stepwise Gatekeeping Procedures in Clinical Trial Applications

  2006cited by this paper
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

  2006cited by this paper
• Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

  2005cited by this paper
• Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.

  2005cited by this paper
• A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.

  2004cited by this paper
• The Measurement and Valuation of Health Status Using EQ-5D: A European Perspective

  2003cited by this paper

• Safety of a remote disease management program to improve sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists prescribing in type 2 diabetes with elevated cardiovascular or kidney risk.

  2026cites this paper
• Real-World Impact of Weekly Dulaglutide and Semaglutide on Hba1c and Weight in a Predominantly Underrepresented Demographic

  2026cites this paper
• The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Cardiovascular-Kidney-Metabolic Syndrome

  2026cites this paper
• Glucagon-like peptide-1 medicines and cancer

  2026cites this paper
• Once-Monthly and Extended-Interval Incretin-, Amylin-, and THRβ-Targeting Therapies for Type 2 Diabetes and Obesity: Clinical Evidence and Development Pipelines

  2026cites this paper
• Agent- and Dose-Specific Intestinal Obstruction Safety of GLP-1 Receptor Agonists and SGLT2 Inhibitors: A Network Meta-Analysis of Randomized Trials

  2026cites this paper
• Exploring the rates of Gastrointestinal adverse effects among five GLP-1 receptor agonists: A systematic review and Meta-Analysis of randomized controlled trials

  2026cites this paper
• Use of glucagon-like peptide-1 receptor agonists and incretin mimetics for type 2 diabetes and obesity: A narrative review.

  2025cites this paper
• Type 2 Diabetes Mellitus: New Pathogenetic Mechanisms, Treatment and the Most Important Complications

  2025cites this paper
• Dulaglutide 1.5 mg Significantly Improves Glycemic Control and Lowers LDL-Cholesterol and Body Weight in Romanian Patients with Type 2 Diabetes

  2025influential citation
• The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis

  2025cites this paper
• Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data

  2025cites this paper
• Association of glucagon-like peptide-1 (GLP-1) receptor agonists and diabetic retinopathy (DR) – a systematic review and meta-analysis

  2025cites this paper
• New generation agents for glycemic control and diabetic retinopathy progression: what we need to know?

  2025influential citation
• Nouveaux médicaments de l’obésité : quelle pertinence ?

  2025cites this paper
• GLP-1-based therapies for diabetes, obesity and beyond

  2025cites this paper
• A Comprehensive Review on the Pharmacokinetics and Drug−Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist

  2025cites this paper
• Efficacy and safety of GLP-1 agonists in Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials

  2025cites this paper
• Oral Small-Molecule GLP-1 Receptor Agonists: Mechanistic Insights and Emerging Therapeutic Strategies

  2025cites this paper
• Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?

  2025cites this paper
• Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?

  2025cites this paper
• The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists

  2025cites this paper
• Efficacy and safety of GLP-1 agonists in the treatment of T2DM: A systematic review and network meta-analysis

  2025cites this paper
• Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo‐controlled clinical trials

  2025cites this paper
• Risk of Hearing Loss in Patients Treated with Exendin-4 Derivatives: A Network Meta-Analysis of Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors

  2025cites this paper
• Efficacy and Safety of Tirzepatide Compared with GLP-1 RAs in Patients with Type 2 Diabetes Treated with Basal Insulin: A Network Meta-analysis

  2025cites this paper
• Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential

  2025influential citation
• Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a Bayesian network meta-analysis

  2025cites this paper
• Targeting the root cause of obesity-related comorbidities through weight independent and dependent actions on insulin sensitivity: Benefits of dual amylin and calcitonin receptor agonists.

  2025cites this paper
• The Preventive Effects of GLP-1 Receptor Agonists and SGLT2 Inhibitors on Cancer Metastasis: A Network Meta-Analysis of 67 Randomized Controlled Trials

  2025cites this paper
• Comparison of the efficacy and safety of GLP‐1 receptor agonists on cardiovascular events and risk factors: A review and network meta‐analysis

  2025cites this paper
• GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?

  2025cites this paper
• Pancreatitis Risk Associated with GLP-1 Receptor Agonists, Considered as a Single Class, in a Comorbidity-Free Subgroup of Type 2 Diabetes Patients in the United States: A Propensity Score-Matched Analysis

  2025cites this paper
• Current status of Liraglutide delivery systems for the management of type 2 diabetes mellitus

  2025cites this paper
• Overcoming barriers to adherence through innovative injectable medications: A systematic review of therapeutic options for cardiovascular disease, reported adherence, and perspectives on their use

  2025cites this paper
• Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?

  2025cites this paper
• Liraglutide preserves endothelial function in ophthalmic arteries of septic mice via prevention of oxidative stress.

  2025cites this paper
• Metformin-mechanisms of its glycemia-reducing effect.

  2025cites this paper
• Sex Differences in the Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta‐Analysis

  2025cites this paper
• Headache and GLP-1 receptor agonists: when medications are therapeutic and when they contribute to the symptom

  2025cites this paper
• GLP-1 agonists in glycemic and weight control of type 2 diabetes. New perspectives.

  2025cites this paper
• Suboptimal physician adherence to evidence‐based guidelines for managing cardiorenal comorbidities in diabetes care: A retrospective single‐center study in Taiwan

  2025cites this paper
• The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP

  2025cites this paper
• A Review and Meta-Analysis of the Safety and Efficacy of Using Glucagon-like Peptide-1 Receptor Agonists

  2024influential citation
• Once-Weekly Insulin Icodec in Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Clinical Trials (ONWARDS Clinical Program)

  2024cites this paper
• Pulse of Progress: A Systematic Review of Glucagon-Like Peptide-1 Receptor Agonists in Cardiovascular Health

  2024cites this paper
• Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists

  2024cites this paper
• Efficacy, adherence and persistence of various glucagon‐like peptide‐1 agonists: nationwide real‐life data

  2024cites this paper
• Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes

  2024influential citation
• Exenatide administration time determines the effects on blood pressure dipping in db/db mice via modulation of food intake and sympathetic activity

  2024cites this paper
• Comparative Efficacy and Safety of Weekly GLP-1/GIP Agonists vs. Weekly Insulin in Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials

  2024cites this paper
• Comparative Analysis of the Anti-Inflammatory Effects of Liraglutide and Dulaglutide.

  2024cites this paper
• Lipid profile changes induced by glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis

  2024cites this paper
• Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node

  2024cites this paper
• Glucagon-like peptide-1 analogs: Miracle drugs are blooming?

  2024cites this paper
• Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide

  2024cites this paper
• Judicious use of modern technology with antihyperglycemic agents: The changing landscape of type 2 diabetes management

  2024cites this paper
• Glucagon-like Peptide-1 Agonists

  2024cites this paper
• Legal, safety, and practical considerations of compounded injectable semaglutide

  2024cites this paper
• Effectiveness and safety of glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes: evidence from a retrospective real-world study

  2024cites this paper
• G protein-coupled receptors driven intestinal glucagon-like peptide-1 reprogramming for obesity: Hope or hype?

  2024cites this paper
• Twenty years of participation of racialised groups in type 2 diabetes randomised clinical trials: a meta-epidemiological review

  2024cites this paper
• Targeting the incretin system in obesity and type 2 diabetes mellitus

  2024influential citation
• Comparative cardiovascular and renal outcomes of Liraglutide versus Dulaglutide in Asian type 2 diabetes patients

  2024cites this paper
• The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and Italy

  2024cites this paper
• Real-World Utilization and Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists Dosed Weekly and Daily in Patients with Type 2 Diabetes Mellitus: Results from Retrospective Electronic Medical Records in China

  2024cites this paper
• Protective effect of Dulaglutide, a GLP1 agonist, on acetic acid-induced ulcerative colitis in rats: involvement of GLP-1, TFF-3, and TGF-β/PI3K/NF-κB signaling pathway

  2024cites this paper
• Bridging the Gap Between Diabetes and Cardiovascular Disease: A Comparative Review of Different Glucagon-Like Peptide-1 (GLP-1) Agonists: Efficacy, Safety, and Patient Outcomes

  2024cites this paper
• Assessing glycemic and weight-lowering potential of oral semaglutide in type 2 diabetes compared to other GLP-1 receptor agonists in Indian context

  2024cites this paper
• Current Status of Glucagon-like Peptide-1 Receptor Agonists in Metabolic Dysfunction-associated Steatotic Liver Disease: A Clinical Perspective

  2024influential citation
• GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach

  2023cites this paper
• Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond

  2023cites this paper
• Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial

  2023cites this paper
• Dulaglutide impedes depressive-like behavior persuaded by chronic social defeat stress model in male C57BL/6 mice: Implications on GLP-1R and cAMP/PKA signaling pathway in the hippocampus.

  2023cites this paper
• Metabolic remodeling of glycerophospholipids acts as a signature of dulaglutide and liraglutide treatment in recent-onset type 2 diabetes mellitus

  2023cites this paper
• Effects of a Dulaglutide plus Calorie-Restricted Diet versus a Calorie-Restricted Diet on Visceral Fat and Metabolic Profiles in Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial

  2023cites this paper
• Use and Interchange of Incretin Mimetics in the Treatment of Metabolic Diseases: A Narrative Review.

  2023cites this paper
• Liraglutide Attenuates Myocardial Ischemia/Reperfusion Injury Through the Inhibition of Necroptosis by Activating GLP-1R/PI3K/Akt Pathway

  2023cites this paper
• Cardio‐renal‐metabolic disease in primary care setting

  2023cites this paper
• The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient‐reported outcomes at 24 months

  2023cites this paper
• Current Weight Loss Medications: What Plastic Surgeons Should Know.

  2023cites this paper
• What Is Best for Weight Loss? A Comparative Review of the Safety and Efficacy of Bariatric Surgery Versus Glucagon-Like Peptide-1 Analogue

  2023cites this paper
• Predictors of efficacy of Sodium‐GLucose Transporter‐2 inhibitors and Glucagon‐Like Peptide 1 receptor agonists: A retrospective cohort study

  2023cites this paper
• The real‐world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24‐month analysis of time to first significant treatment change, treatment persistence and clinical outcomes

  2023influential citation
• Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review

  2023cites this paper
• Natural compounds efficacy in complicated diabetes: A new twist impacting ferroptosis.

  2023cites this paper
• Glucometabolic control of once-weekly dulaglutide switched from DPP4 inhibitor versus daily empagliflozin add-on in patients with type 2 diabetes inadequately controlled with metformin, sulfonylurea, and DPP4 inhibitor: a randomised trial.

  2023cites this paper
• Clinical Characteristics Associated with Adherence and Persistence in Patients with Type 2 Diabetes Mellitus Treated with Dulaglutide

  2023influential citation
• Uncoupling hepatic insulin resistance – hepatic inflammation to improve insulin sensitivity and to prevent impaired metabolism-associated fatty liver disease in type 2 diabetes

  2023cites this paper
• A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications

  2023cites this paper
• Glucagon-like peptide-1 analogues: a new way to quit smoking? (SKIP)—a structured summary of a study protocol for a randomized controlled study

  2023cites this paper
• Efficacy and safety profile of Glucagon-Like Peptide-1 Receptor Agonist in obese Type-2 diabetes patients from a private institution in Karachi

  2023cites this paper
• What is Glycaemic Variability and which Pharmacological Treatment Options are Effective? A Narrative Review

  2023cites this paper
• Treating obesity in type 1 diabetes mellitus – review of efficacy and safety

  2023cites this paper
• Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis

  2022cites this paper
• Glucagon-Like Peptide 1 Receptor Agonists Have the Potential to Revolutionize the Attainment of Target A1C Levels in Type 2 Diabetes—So Why Is Their Uptake So Low?

  2022cites this paper
• Effects of dulaglutide on endothelial progenitor cells and arterial elasticity in patients with type 2 diabetes mellitus

  2022cites this paper
• Cardiovascular effects of incretins - focus on GLP-1 receptor agonists.

  2022cites this paper
• GLP-1 Receptor Agonists Critical Review: Revisiting Its Positioning for Type 2 Diabetes Mellitus in Routine Clinical Practice in India

  2022cites this paper
• Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group.

  2022cites this paper